Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq ease from record highs as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
November 8, 2018 4:06 PM EST-- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise ---- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance ---- Amends and Strengthens Commercial Agreement with Collegium ---- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --
LAKE FOREST, Ill., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended September 30, 2018, and provided an update on its business performance and strategic initiatives.
Our third-quarter performance positions us well to... More



